Markus P. Radsak

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 479 citations

Medicine, Oncology, Pharmacology +11

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Uwe Platzbecker, Ulrich Germing, Katharina S. Götze et al. · The Lancet Oncology · 2017 · 288 citations

Medicine, Hematology, Pharmacology +8

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

M. Hipp, Norbert Hilf, Steffen Walter et al. · Blood · 2008 · 286 citations

Medicine, Oncology, Pharmacology +14

Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease

Susanne Karbach, Andrew L. Croxford, Matthias Oelze et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2014 · 256 citations

Medicine, Dermatology, Immunology +10

Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo

Tobias Warger, Philipp Osterloh, Gerd Rechtsteiner et al. · Blood · 2006 · 241 citations

Life Sciences, Cancer Biology, Immunology +14